Algert Global’s Revance Therapeutics, Inc. RVNC Stock Holding History

Algert Global’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-183,108	Closed	-$557K	–	1366
2024 Q4	$557K	Buy	183,108 +56,378	+44%	+$246K	0.01%	887
2024 Q3	$658K	Buy	126,730 +116,730	+1,167%	+$580K	0.02%	846
2024 Q2	$26K	Sell	10,000 -127,260	-93%	-$435K	﹤0.01%	1472
2024 Q1	$675K	Sell	137,260 -6,780	-5%	-$40.1K	0.03%	711
2023 Q4	$1.27M	Buy	+144,040	New	+$1.18M	0.05%	559

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Algert Global's RVNC Position: Q1 2025 in Review

Algert Global sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 183,108 shares — an estimated $557K sold.

Algert Global first reported a position in RVNC in Q4 2023 and held it in 5 quarters. The position peaked at $1.27M in Q4 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Algert Global reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Algert Global sold 183,108 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $557K.
Algert Global first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 5 quarters.
Algert Global's Revance Therapeutics, Inc. position peaked at $1.27M in Q4 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Algert Global's 13F filing for Q1 2025, filed 13 May 2025.